Literature DB >> 17400200

Olfactory abnormalities in Huntington's disease: decreased plasticity in the primary olfactory cortex of R6/1 transgenic mice and reduced olfactory discrimination in patients.

Stanley E Lazic1, Anna O G Goodman, Helen E Grote, Colin Blakemore, A Jennifer Morton, Anthony J Hannan, Anton van Dellen, Roger A Barker.   

Abstract

Reduced neuronal plasticity in the striatum, hippocampus, and neocortex is a common feature of transgenic mouse models of Huntington's disease (HD). Doublecortin (DCX) and polysialylated neural cell adhesion molecule (PSA-NCAM) are associated with structural plasticity in the adult mammalian brain, are markers of newly formed neurons in the dentate gyrus of the adult hippocampus, and are highly expressed in primary olfactory (piriform) cortex. Animal studies have demonstrated that a reduction in plasticity in the piriform cortex is associated with a selective impairment in odour discrimination. Therefore, the number of DCX and PSA-NCAM immunoreactive cells in the piriform cortex were quantified as measures of plasticity in early stage (fifteen week old) R6/1 transgenic HD mice. The transgenic mice had a large reduction in the number of DCX and PSA-NCAM immunoreactive cells in the piriform cortex, similar to that previously reported in the R6/2 mice. We also tested whether odour discrimination, as well as identification and detection, were impaired in HD patients and found that patients (at a similar disease stage as the mice) had an impairment in odour discrimination and identification, but not odour detection. These results suggest that olfactory impairments observed in HD patients may be the result of reduced plasticity in the primary olfactory cortex.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17400200     DOI: 10.1016/j.brainres.2007.03.018

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  22 in total

1.  General olfactory sensitivity database (GOSdb): candidate genes and their genomic variations.

Authors:  Ifat Keydar; Edna Ben-Asher; Ester Feldmesser; Noam Nativ; Arisa Oshimoto; Diego Restrepo; Hiroaki Matsunami; Ming-Shan Chien; Jayant M Pinto; Yoav Gilad; Tsviya Olender; Doron Lancet
Journal:  Hum Mutat       Date:  2012-10-11       Impact factor: 4.878

2.  Ciliogenesis is regulated by a huntingtin-HAP1-PCM1 pathway and is altered in Huntington disease.

Authors:  Guy Keryer; Jose R Pineda; Géraldine Liot; Jinho Kim; Paula Dietrich; Caroline Benstaali; Karen Smith; Fabrice P Cordelières; Nathalie Spassky; Robert J Ferrante; Ioannis Dragatsis; Frédéric Saudou
Journal:  J Clin Invest       Date:  2011-10-10       Impact factor: 14.808

Review 3.  Centriolar satellites: key mediators of centrosome functions.

Authors:  Maxim A X Tollenaere; Niels Mailand; Simon Bekker-Jensen
Journal:  Cell Mol Life Sci       Date:  2014-08-31       Impact factor: 9.261

Review 4.  Modeling Huntington's disease with induced pluripotent stem cells.

Authors:  Julia A Kaye; Steven Finkbeiner
Journal:  Mol Cell Neurosci       Date:  2013-02-28       Impact factor: 4.314

5.  Impaired adult olfactory bulb neurogenesis in the R6/2 mouse model of Huntington's disease.

Authors:  Zacharias Kohl; Martin Regensburger; Robert Aigner; Mahesh Kandasamy; Beate Winner; Ludwig Aigner; Jürgen Winkler
Journal:  BMC Neurosci       Date:  2010-09-13       Impact factor: 3.288

6.  The Neurotransmitter Receptor Architecture of the Mouse Olfactory System.

Authors:  Kimberley Lothmann; Katrin Amunts; Christina Herold
Journal:  Front Neuroanat       Date:  2021-04-23       Impact factor: 3.856

7.  Selective neuronal requirement for huntingtin in the developing zebrafish.

Authors:  Tanya L Henshall; Ben Tucker; Amanda L Lumsden; Svanhild Nornes; Michael T Lardelli; Robert I Richards
Journal:  Hum Mol Genet       Date:  2009-09-29       Impact factor: 6.150

8.  CD73 is a major regulator of adenosinergic signalling in mouse brain.

Authors:  Natalia Kulesskaya; Vootele Võikar; Marjaana Peltola; Gennady G Yegutkin; Marko Salmi; Sirpa Jalkanen; Heikki Rauvala
Journal:  PLoS One       Date:  2013-06-12       Impact factor: 3.240

Review 9.  Mouse models of polyglutamine diseases: review and data table. Part I.

Authors:  Maciej Figiel; Wojciech J Szlachcic; Pawel M Switonski; Agnieszka Gabka; Wlodzimierz J Krzyzosiak
Journal:  Mol Neurobiol       Date:  2012-09-07       Impact factor: 5.590

10.  Visualising disease progression on multiple variables with vector plots and path plots.

Authors:  Stanley E Lazic; Sarah L Mason; Andrew W Michell; Roger A Barker
Journal:  BMC Med Res Methodol       Date:  2009-05-27       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.